- PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies
-
Miller RE, El-Shakankery KH, Lee JY
- KMID: 2536999
- J Gynecol Oncol.
- 2022 May;33(3):e44.
- doi: 10.3802/jgo.2022.33.e44
The use of PARP inhibitors (PARPi) in patients with epithelial ovarian cancer is expanding, with the transition from use in recurrent disease to the first-line setting. This is accompanied with... -
- CITED
-
- Close
- SHARE
-
- Close
